JPX · 4597.T
Solasia Pharma K.K.
¥27-¥1 (-3.57%)
Solasia Pharma K.K.’s quoted price sits in the lower half of its reported 52-week range, 35.71% below the high.
Loading market information…
JPX · 4883.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Modalis Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 66.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Modalis Therapeutics Corporation’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Modalis Therapeutics Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥27-¥1 (-3.57%)
Solasia Pharma K.K.’s quoted price sits in the lower half of its reported 52-week range, 35.71% below the high.
¥2,550-¥11 (-0.43%)
WDB coco Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 9.73% below the high.
¥845+¥1 (+0.12%)
Shigematsu Works Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.27% below the high.
¥501-¥1 (-0.2%)
Pharmarise Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 9.57% below the high.
¥559-¥5 (-0.89%)
Cyfuse Biomedical K.K.’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
¥1,515¥0 (0.0%)
Nippon Chemiphar Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.42% below the high.
¥132+¥2 (+1.54%)
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
